HC Wainwright & Co. Maintains Buy on ADC Therapeutics, Lowers Price Target to $3

Benzinga ·  11/20/2023 23:31

HC Wainwright & Co. analyst Robert Burns maintains ADC Therapeutics (NYSE:ADCT) with a Buy and lowers the price target from $12 to $3.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment